Prelude Therapeutics IPO

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Register for Details

For more details on financing and valuation for Prelude Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Prelude Therapeutics's ticker symbol?


What is Prelude Therapeutics's stock price?

3.04 as of 9/28/23

Learn more about Prelude Therapeutics

Forge green plus iconForge green minus icon

What is Prelude Therapeutics funding to date?

Prelude Therapeutics has raised $95MM to date.
Forge green plus iconForge green minus icon

When was Prelude Therapeutics founded?

Prelude Therapeutics was founded in 2016.
Updated on: Jun 12, 2022